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Abstract
Setting: This study was conducted in a high tuberculosis (TB) burden area in Worcester, South Africa, with a notified all TB
incidence rate of 1,400/100,000.
Main Objective: To compare the predictive value of a baseline tuberculin skin test (TST) with that of the QuantiFERON TB
Gold (In-tube) assay (QFT) for subsequent microbiologically confirmed TB disease among adolescents.
Methods: Adolescents aged 12–18 years were recruited from high schools in the study area. At baseline, blood was drawn
for QFT and a TST administered. Participants were followed up for up to 3.8 years for incident TB disease (median 2.4 years).
Results: After exclusions, 5244 (82.4%) of 6,363 adolescents enrolled, were analysed. The TB incidence rate was 0.60 cases
per 100 person years (pyrs) (95% CI 0.43–0.82) for baseline TST positive ($5 mm) participants and 0.64 cases per 100 pyrs
(95% CI 0.45–0.87) for baseline QFT positive participants. TB incidence rates were 0.22 per 100 pyrs (0.11–0.39) and 0.22 per
100 pyrs (0.12–0.38) among those with a negative baseline TST and QFT respectively. Sensitivity for incident TB disease was
76.9% for TST and 75.0% for QFT (p=0.81). Positive predictive value was 1.4% for TST and 1.5% for QFT.
Conclusion: Positive TST and QFT tests were moderately sensitive predictors of progression to microbiologically confirmed
TB disease. There was no significant difference in the predictive ability of these tests for TB disease amongst adolescents in
this high burden setting. Therefore, these findings do not support use of QFT in preference to TST to predict the risk of TB
disease in this study population.
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Introduction
Latent tuberculosis (TB) infection has historically been diag-
nosed with a tuberculin skin test (TST). However, with this
method, cross reactivity with BCG and non tuberculous
mycobacteria (NTMs) undermines the specificity of the test[1].
As an alternative to the TST, interferon c release assays (IGRAs)
have been developed which utilise antigens not present in BCG
and most non-tuberculous mycobacteria (NTMs)[2]. The advan-
tages of these assays over TSTs are: a second visit for reading of
the test is no longer necessary; boosting due to repeated testing is
avoided; they have greater specificity for latent TB infection; and
they are less prone to the biases encountered when measuring the
size of skin reactions, such as digit preference[3]. However, IGRAs
are more expensive, need a blood draw and require a sophisticated
laboratory.
The QuantiFERON TB Gold (In-tube method) (Cellestis
Limited, Carnegie, Victoria, Australia) is one such commercially
available assay which has been adopted by many countries as an
alternative to TST or as part of a two step approach which uses
both tests – a TST is done first and those with a positive test result,
have a QuantiFERON done. QuantiFERON TB Gold (In-tube
method) (QFT) uses ESAT-6, CFP10 and antigen 7.7 of
mycobacterium tuberculosis as stimuli to determine if T cells in whole
blood are sensitized to such antigens thus indicating prior exposure
and/or evidence of latent tuberculosis infection.
The predictive value of a positive tuberculin skin test (TST) for
TB disease has been shown in isoniazid prevention trials and
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17984contact investigations[4,5,6]. When our study was initiated, there
was a call to conduct longitudinal studies with the new assays so as
to determine their validity in predicting TB disease[7,8]. Some
longitudinal studies have been done to date but the results have
been contradictory in that some show a better predictive ability for
the IGRAs than for the TST while others show no difference
between them[9,10,11,12,13,14,15]. Most of these studies were
designed as follow up of contacts of cases diagnosed with TB so it is
not clear what the relative value of these tests would be in a
general population setting.
We conducted a longitudinal study to determine the predictive
value for subsequent TB disease of QFT compared to TST in a
large cohort of adolescents in a high burden setting. The baseline
characteristics of this adolescent cohort have been published with
55.2% of participants being TST positive (using a 5 mm cutoff) and
50.9% being QFT positive at baseline[16]. Adolescents are
currently under investigation as a target group for TB vaccines
and the predictive value of interferon gamma release assays for the
subsequent onset of TB disease will be helpful in planning clinical
trials of novel TB vaccines. Such data are also necessary for policy
makers, researchers, and clinicians developing guidelines for the use
of such tests in TB control programmes and in clinical practice.
Methods
Ethics Statement
Written informed consent was obtained from the parents of
participating adolescents and written informed assent obtained
from each adolescent. This study was approved by the Faculty of
Health Sciences Human Research Ethics Committee, University
of Cape Town. Isoniazid prevention therapy (IPT) is not standard
of care in South Africa for individuals with latent tuberculosis
infection except for infants under the age of 5 and HIV infected
persons (National Tuberculosis Management Guidelines, Depart-
ment of Health, South Africa 2009). Participants with a positive
TST or QFT were investigated for TB disease and referred for
treatment at public sector facilities if needed.
Study setting
The study took place at an established TB vaccine trial site in
the town of Worcester (and surrounding villages) approximately
100 km from Cape Town. This area has a high burden of TB with
a total notified TB incidence rate among all ages of approximately
1,400 per 100,000 population, based on official TB programme
data for 2006 [17].
Study subjects
Adolescents aged 12 to 18 years were recruited from high
schools in the study area. They were not participating in a TB
vaccine trial at the time of this study.
Study procedures
emographic data were collected at baseline, as well as data on
current and prior household TB contact. At baseline, blood was
drawn for QuantiFERONH TB Gold In-tube (Cellestis). A
tuberculin skin test was then immediately administered using the
Mantoux method on either forearm, using 2 tuberculin units of
RT23 (Statens Serum Institut, Denmark). Induration at the TST
site was read 48–96 hours later with a ruler or a caliper by trained
study personnel. Those with previous or current TB did not have a
TST performed, because of the increased risk of severe allergic
reactions. The QuantiFERON test (QFT) was performed as
recommended by the manufacturers. Any participant who had TB
related symptoms, a recent household contact, a positive TST
$10 mm induration or a positive QFT were referred for two
sputum smears. If either or both were sputum positive for acid fast
bacilli, the sputums were cultured, a chest x-ray performed and an
HIV test done. Those diagnosed with TB were referred to the
public health services for evaluation and treatment. About half of
participants were allocated to active follow up three monthly and
half to passive follow up being seen at baseline and at their two
year visit only. At follow up visits, those with new symptoms, a new
Table 1. Demographic profile of study participants analysed
(n=5244).
Category Numbers (column %)
Gender
Male 2,402 (45.8%)
Female 2,842 (54.2%)
Age (years)
.15 2,261 (43.1%)
#15 2,983 (56.9%)
Racial group
Black 995 (19.0%)
Mixed race 3,839 (73.2%)
Indian/white 410 (7.8%)
Parent income: classified on at least one parent’s income
#R4000/month 4,243 (80.9%)
.R4000/month 921 (17.6%)
Unknown 80 (1.5%)
Maternal highest education level
# Primary school 1,510 (28.8%)
$ High school 2,890 (55.1%)
Unknown: 844 (16.1%)
Paternal highest education level
# Primary school 686 (13.1%)
$ High school 1,720 (32.8%)
Unknown: 2,838 (54.1%)
BCG reported as being given
No 46 (0.9%)
Yes 4,917 (93.8%)
Unknown 281 (5.4%)
BCG scar
Absent 1,490 (28.4%)
Present 2,064 (39.4%)
Unknown (Not sure) 1,690 (32.2%)
Current or prior TB household contact
Yes 1,332 (25.4%)
No 3,911 (74.6%)
Unknown 1 (0.02%)
Chronic allergy-related conditions e.g. asthma, hay fever, eczema
Yes 53 (1.0%)
No 5,191 (99.0%)
History of hospitalization within the 6 months prior to enrolment
Yes 46 (0.9%)
No 5,198 (99.1%)
doi:10.1371/journal.pone.0017984.t001
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baseline) or a converted QFT test (change from negative to
positive) were investigated for active TB. Investigation for TB
included two sputum samples for smear microscopy on two
separate occasions. If any single sputum was smear positive, a
mycobacterial culture, chest x-ray, and HIV test were performed.
In addition, surveillance was conducted at TB clinics and of
hospital registers in the area to find any TB cases diagnosed in
between visits in all participants. All subjects were scheduled to be
seen for a two-year close-out visit unless they were lost to follow up
or had died. Due to financial constraints, a small proportion of
two-year visits were brought forward at the end of the study.
Follow up was therefore continued for a minimum of 22 months.
Those completing ‘‘two-year’’ visits were still observed for the
occurrence of cases through surveillance of health facility records
until the last subject had their final visit, giving a maximum follow
up time of 3.8 years. The study took place from 2005 to 2009.
Analysis
Data were captured in a Microsoft Access database and analysed
with STATA version 11.0 (Statacorp, Texas, USA). A TST cutoff of
5 mm was used to define a positive or negative test based on the
distribution of TST indurations[16]. Analyses based on the 10 mm
and 15 mm cutoffs are also given. A QuantiFERON value of 0.35
international units or more was deemed positive as per manufactur-
er’s specifications. Any participant diagnosed with pulmonary TB
based on at least two positive sputum smears or a single positive
sputum culture was defined as a case of TB. Incidence rates were
calculated by dividing the number of incident cases by the total
person time of observation. Observation time was calculated from
date of enrolment to study end date except where there was loss to
follow up, diagnosis of TB, consent withdrawal or death. When there
was loss to follow up, person time of observation was calculated from
baseline to a halfway point between the date when last seen and the
date of the nextscheduled visit when loss to follow up was established.
95% confidence intervals for incidence rates were calculated using
Poisson regression. Incidence rate ratios (IRRs) were then calculated
and the 95% confidence interval for each IRR was calculated.
Exposure to TB was based solely on reported household TB contact
at baseline. Reported time between household TB contact and
enrolment was calculated by subtracting the year of reported contact
from the year of enrolment. The sample size for this study was based
on estimation of an incidence rate that would be useful for planning
clinical trials of new TB vaccines in adolescents. The sample size
analysed would have been sufficient to detect a significant difference
in predictive value between the TST positive and QFT positive
groups at an incidence rate ratio of 1.54 given an incidence rate of
0.60 per 100 person years in the TST positive group.
Results
Study participants
6,363 participants were enrolled at baseline but after exclusion
of those with prior or current TB, indeterminate QFT results, or
missing QFT or TST results, as described elsewhere[16], 5,244
participants were included in this analysis. 82% of participants
completed follow up at two years. Of the 18% of participants who
did not complete their two year visits, 8 (0.2%) had died during
follow up. More detail on attendance at follow up visits and
reasons for visits not being completed is provided separately as
Table S1. Mean follow up time was 2.3 years, median 2.4 years
and range 1.5 to 46 months (3.8 years). The most common reason
for non-participation in this study when a reason was given was
fear of blood draws. Important baseline characteristics of the
recruited population were as follows: 54.2% female, 56.9% under
the age of 16, 93.8% reported having received BCG at birth and
25.4% reported a prior or current household contact. More details
on baseline characteristics are laid out in Table 1.
Baseline TST and QFT results
There was good agreement at baseline between QFT and TST
at the 5 mm (84.8%, kappa 0.70) and 10 mm cutoff (81.4%, kappa
0.63) but not the 15 mm cutoff (64.3%, kappa 0.30) (details
described elsewhere[16]).
Incident cases and rates by TST/QFT status
67 participants were diagnosed with TB, of whom 52 met the a
priori case definition and 42 were culture positive. Percentage
agreement between TST and QFT among the 52 cases was 86.5%
(kappa 0.63). The incidence rates of TB by baseline QFT and TST
status are shown in Table 2 and Figure 1. These show that the TB
incidence rate was 0.60 cases per 100 person years (pyrs) (95%
confidence interval [CI] 0.43–0.82) for baseline TST positive
($5 mm) participants and 0.64 cases per 100 pyrs (95% CI 0.45–
0.87) for baseline QFT positive participants. There were 7 cases
diagnosed within 6 months of enrolment and excluding these
changed the rates to 0.53 (95% CI 0.37–0.73) and 0.55 (95% CI
0.38–0.77) cases per 100 pyrs for positive TSTs and QFTs
Table 2. Incidence rates by TST ($5 mm) and QFT status at baseline.
N Incident TB Cases
Person years of
follow up
Incidence Rate (per
100 person years, 95%CI)
No of persons followed
up per year to detect 1 case
TST+ 2,894 40 6651 0.60 (0.43–0.82) 166
QFT+ 2,669 39 6137 0.64 (0.45–0.87) 157
TST2 2,350 12 5337 0.22 (0.11–0.39) 444
QFT2 2,575 13 5851 0.22 (0.12–0.38) 450
TST+/QFT+ 2,383 36 5480 0.66 (0.46–0.91) 152
TST2/QFT+ 286 3 657 0.46 (0.09–1.33) 219
TST+/QFT2 511 4 1171 0.34 (0.09–0.87) 293
TST2/QFT2 2,064 9 4680 0.19 (0.09–0.37) 520
Total* 5,244 52 11988 0.43 (0.32–0.57) 231
*all participants analysed.
doi:10.1371/journal.pone.0017984.t002
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incidence rate of 0.74 per 100 pyrs (95% CI 0.53–1.02) in
participants with a baseline TST $10 mm (42.2% of participants).
There was a significantly higher rate of TB in those with a positive
QFT or TST than in those with a corresponding negative test result.
The incidence rate ratios (IRRs) were 2.7 (95% confidence interval
[CI]1.4–5.0) for TST (IncidenceRate(IR)TST+/IR TST-)and 2.9
(95% CI 1.6–5.2) for QFT (IR QFT+/IR QFT-). The number of
persons that needed to be tested for TST and/or QFT and followed
up to predict one TB caseover a period of one yearranged from 157
to 520 depending on the test result. The proportion of cases who
were test positive and diagnosed with TB within the first year
comparedtosubsequentyearswas84.2%versus72.7%(p=0.34)for
TST and 73.7% versus 75.8% (p=0.86) for QFT respectively.
Sensitivity, specificity, positive predictive value and
negative predictive value (Table 3)
Approximately three quarters of cases, 76.9% for TST and
75.0% for QFT (p=0.81), were test positive at baseline. Specificity
was less than 50% for both tests: 45.0% for TST and 49.3% for
QFT (p,0.01). While this constituted a statistically significant
difference, it was not viewed as clinically relevant. The positive
predictive value was similarly very low for both (TST 1.4% and
QFT 1.5%) and the negative predictive value was equally high for
both tests (99.5%).
Relationship between time of exposure and risk of
disease
In one subset of participants (n=1328) for whom a history of a
household TB contact was reported at baseline, the prevalence of a
positive baseline TST and QFT was significantly and negatively
associated with time since TB contact exposure (Table 4); i.e. the
longer the time since last recalled contact, the lower the proportion
with a positive result on either test. Of 20 cases for whom a TB
contact prior to enrolment was reported, 15 (75.0%) had had a
contact less than 5 years before enrolment and 5 (26.3%), 5 years
or more. The proportion positive TST and QFT results among
cases who reported recent compared to remote contacts were
similar. Rates of disease were higher amongst those more recently
exposed than among those exposed $5 years or more previously.
These differences were not significant since all incidence rate ratios
had very wide confidence intervals which included one (Table 5).
Discussion
This is the largest study investigating the predictive value of
TST versus an IGRA and it is one of few from a high burden
setting (Table 6). A positive TST and QFT were both indicative of
a higher risk of developing subsequent TB disease, and were
equivalent in predicting incident TB disease. While the sensitivity
was moderate, specificity and positive predictive values were
relatively low, and negative predictive values were high. There was
a trend for more recent reported exposure (,5 years) to be
Figure 1. Incidence rates by baseline TST and QFT status. Figure 1 is a chart of incidence rates of tuberculosis per 100 person years of
observation by baseline TST and QFT status. Firstly, rates are shown individually for either positive or negative TST or QFT result. Then rates are shown
with combined results, either concordant negative or positive TST and QFT results, or discordant negative/positive combinations.
doi:10.1371/journal.pone.0017984.g001
Table 3. Sensitivity, specificity, positive predictive value and
negative predictive value of TST and QFT for predicting TB
disease.
TST % (95% CI) QFT %(95% CI)
Sensitivity 76.9 (63.6–87.5) 75.0 (61.1–86.0)
Specificity 45.0 (43.7–46.4) 49.3 (48.0–50.7)
Positive Predictive value 1.4 (1.0–1.9) 1.5 (1.0–2.0)
Negative predictive value 99.5 (99.1–99.7) 99.5 (99.1–99.7)
doi:10.1371/journal.pone.0017984.t003
Table 4. Proportion TST and QFT positive by time since
recalled exposure to household TB contact (N=1,328).
QFT positive (%) TST positive (%)
0–4 years (n=890) 69.4 72.3
5–9 years (n=235) 65.1 72.8
10–14 years (n=168) 57.1 67.3
$15 years (n=35) 57.1 54.3
Chi squared for trend: p,0.001 P=0.036
doi:10.1371/journal.pone.0017984.t004
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but the confidence intervals were very wide.
This study is significant in that most of the other longitudinal
studies examining this question were based largely on household
contacts of TB cases[9,10,12,13,15,18,19,20] while those using a
cohort methodology were much smaller by comparison[11,14].
The finding in this study of a similar predictive value for QFT and
TST accords with that of studies in Turkey, the Gambia, Senegal,
Norway and the Netherlands [10,11,12,13,15], but contradicts the
findings of the studies from Germany and Hong Kong[9,14]. It is
thus still unclear whether IGRAs offer better predictive value for
subsequent TB disease than the TST. There is increasing evidence
that IGRAs perform differently in high burden compared to low
burden countries and this may partly explain the differences seen
amongst the different studies[21]. The study in The Netherlands
was done amongst immigrants and the one in Norway amongst
asylum seekers, populations that represent high incidence home
countries rather than low incidence host countries[11,13]. In
Table 5. Incidence rates by time since recalled exposure to household TB contact.
Time since
contact
Numbers reporting
contact n=1,328 Incident cases
Incidence rate per
100 person years
QFT + incident
cases
QFT + incidence
rate per 100
person years
TST + incident
cases
TST + incidence
rate per 100
person years
Recent ,5 years 890 15 0.74 15 1.07 14 0.95
Remote $5 years 438 5 0.49 3 0.48 4 0.56
Incidence rate ratio 1.5 2.2 1.7
(Recent/remote) (95% confidence intervals) (0.5–5.3) (0.6–11.9) (0.5–7.0)
doi:10.1371/journal.pone.0017984.t005
Table 6. A summary of longitudinal studies comparing the predictive value of TSTs and IGRAs.
Authors, Country
and Year of
publication Study Type Number
Population
description Cases
Length of
Follow up
Products and TST
cutoffs
Baseline
prevalence
Cumulative incidence (%)
or Incidence rate per 100
person years (pyrs)*
R Diel et al.
Germany (2010)
Contact
investigation
903 All ages - range
1–62
19 Up to 4 yrs TST $5 mm 63% 3.2%
TST $10 mm 25% 4.8%
QFT 21% 12.9%
P Hill et al.
Gambia (2008)
Contact
investigation
2348 All ages 26 2 yrs TST $10 mm 36% 0.9/100 pyrs
Elispot 28% 0.9/100 pyrs
S Kik et al. The
Netherlands (2009)
Contact
investigation
339 Immigrants
$16 years
9 2 yrs TST $10 mm 54% 3.1%
QFT 55% 2.8%
T-Spot 63% 3.3%
M Bakir et al.
Turkey (2009)
Contact
investigation
908 Age #16 years 15 2 yrs TST $5 mm 61% 1.7/100 pyrs
Elispot 42% 2.1/100 pyrs
CC Leung et al.
Hong Kong (2010)
Cohort study 308 Adult males
with silicosis
17 1–5 yrs TST $5 mm 74% 2.3/100 pyrs
TST $10 mm 66% 2.6/100 pyrs
T - Spot 66% 3.2/100 pyrs
C Lienhardt et al.
Senegal (2010)
Contact
investigation
2679 All ages 52 2 yrs TST $5 mm 78% 1.5/100 pyrs
TST $10 mm 65% 1.2/100 pyrs
TST $15 mm 37% 1.6/100 pyrs
Elispot 65% 1.4/100 pyrs
H del Corral et al.
Colombia (2009)
Contact
investigation
2052 All ages 37 2–3 yrs Elisa (IFN-c responses
to CFP-10)
66.3% 0.8/100 pyrs
H Mahomed et al.
South Africa
Cohort study 5244 Adolescents
aged 12–18
52 2–4 yrs TST $5 mm 55% 0.6/100 pyrs
TST $10 mm 42% 0.7/100 pyrs
QFT 51% 0.6/100 pyrs
*Incidence rates adjusted to per 100 person years from original articles to enable comparison.
doi:10.1371/journal.pone.0017984.t006
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to active TB cases, the greater specificity of IGRAs is apparently
not useful. Also, where BCG is given at birth as is common in high
burden countries, it has been shown that the effect of BCG on the
TST is limited after the age of 10 and the TST thus retains its
specificity[22]. These tests may therefore perform better in low
incidence settings. Therefore, many low incidence countries have
shifted to using IGRAs.
Table 6 summarises the studies comparing the predictive value
of TST and IGRAs for TB disease and includes the data from this
study. There are important differences amongst the studies –
different products are compared, different cutoffs are used for TST
and different populations have been studied. These design and
measurement differences may also explain some of the different
results obtained. This limits the degree to which these studies are
comparable.
The TB incidence rates in our cohort study are lower than in
the contact investigation studies. Contacts are likely to have been
more recently exposed whereas in a cohort study, time since
exposure will vary. Recent contacts are at higher risk of
progressing to disease within the first two to five years of follow
up as demonstrated in early studies in the USA which give a 10
year rate of disease of 36.9 per 1000 amongst household contacts
compared to a 10 year rate of 6.6 in a cohort of mental patients
who were followed up[4]. In the household contact group in this
American paper, most cases occurred in the first 5 years of follow
up. The kind of cohort study reported in this manuscript helps to
quantify risk in a clinical context where time since exposure is
often not known.
The lower proportion of TST and QFT positive results in those
with a longer reported time between exposure and latent TB
infection measurement by TST and QFT indicates waning of
responses to tuberculosis antigens over time although this may also
be affected by recall bias. When we examined risk of progression
to disease in those who reported a prior household contact, there
was a trend towards an increased risk in those with recent
exposure but this was not significant. This study may have been
inadequately powered to detect this difference. Also, one would
need to recognize that in this community, the high burden of TB
means that exposure is likely to be a common occurrence whether
reported or not. A study amongst immigrants to the Netherlands
showed that remote exposure is common particularly among those
from high burden settings[23].
There was no difference in proportion TST or QFT positive at
baseline between cases diagnosed in the first year after enrolment
versus those diagnosed afterwards. This may be due to the fact that
follow up was not continued for long enough to detect a drop off in
risk. The studies reviewed by Ferebee show a sustained high risk in
those with a recent contact in the first five years of follow up before
the risk starts declining[4].
Despite the higher risk of subsequent TB represented by a
positive TST or QFT, the number of people that must be
followed up and screened for TB in order to find a single case is
substantial, even in this high burden setting where infections
and re-infections are common[24]. The cost effectiveness of
such population screening would need to be evaluated,
including the value of treating test positive persons with
isoniazid preventive therapy to prevent the onset of future TB
disease. Given that across most studies, more than 95% of
persons who are IGRA positive do not progress to TB disease,
emphasises the need for biomarkers other than interferon
gamma for risk prediction, or a combination of interferon
gamma with risk factors (e.g. age, contact history, conversion) to
enhance predictive value.
Positive and negative predictive values are dependent on
prevalence. Since a low positive predictive value was achieved in
a high burden setting, an even lower PPV can be expected in a low
burden setting. The findings on sensitivity, specificity, positive and
negative predictive value are similar to those in The Netherlands
study[13] while the other studies did not describe these. While a
positive test is not very helpful in predicting disease, a negative test
suggests that risk of progression to disease is low although it does
not rule out the possibility entirely.
These results are not representative of adolescents with prior TB
since they were excluded from having a TST. Since those with
past TB are at higher risk of getting TB again, our incidence rates
are probably all underestimated. Since those with past TB are also
more likely to be TST and QFT positive, it is unclear how
sensitivity, specificity, PPV and NPV would change, had we
included those. Also, any of those negative at baseline could have
converted during study follow up due to new exposures prior to
the onset of TB disease and would be misclassified as test negative.
There is no reason to think that this would have occurred
differentially between the tests. Those with a positive TST or QFT
at baseline were investigated for TB. If diagnosed with TB, they
were not included in the 5244 participants analysed in this
predictive analysis. Those with a QFT or TST conversion were
investigated at follow up and if diagnosed were included in the
analysis. However, most cases (.80%) were diagnosed by local
health services who would not normally have enquired about TST
and QFT results since these are not routinely used in the diagnosis
of TB in this age group. Therefore neither incorporation bias nor
lack of blinding were felt to be major factors influencing the
analysis. While the screening methods for TB at baseline were
insensitive for smear negative culture positive TB, a sensitivity
analysis which excluded cases diagnosed within six months of
enrolment did not appreciably change the main findings showing
no difference in the predictive value of TST versus QFT for TB
disease. Not all participants completed follow up; if any of these
had developed TB, this may have influenced the findings in that
rates would have been higher. Finally, since recruitment took place
at schools and a substantial proportion (41.8%) did not participate,
these results are not representative of all adolescents in this area.
None of these limitations are thought to affect the comparison
between TST and QFT in this study.
These findings suggest TST and QFT are equally predictive of
progression to TB disease in a cohort of adolescents in a high TB
burden population and may be used interchangeably. Our results
do not support the hypothesis that QFT is superior to TST in its
predictive value. These findings should assist policy makers
attempting to develop guidelines for IGRA use in high and low
TB burden countries. More studies in high burden settings and in
adolescents are needed to indicate whether either the TST or
QFT may be used as a screening tool in planning TB vaccine trials
in adolescents.
Supporting Information
Table S1 Flow of visits and reasons for visits not taking
place. This table describes frequency of visits, the number of visits
at each time point and the reasons for visits not being completed.
It also provides the number for each reason with percentages.
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